Esperion Therapeutics, Inc.

NasdaqGM ESPR

Esperion Therapeutics, Inc. Free Cash Flow Yield on January 14, 2025: -5.91%

Esperion Therapeutics, Inc. Free Cash Flow Yield is -5.91% on January 14, 2025, a 79.04% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Esperion Therapeutics, Inc. 52-week high Free Cash Flow Yield is -1.84% on July 16, 2024, which is 68.82% above the current Free Cash Flow Yield.
Esperion Therapeutics, Inc. 52-week low Free Cash Flow Yield is -39.20% on January 30, 2024, which is -563.57% below the current Free Cash Flow Yield.
Esperion Therapeutics, Inc. average Free Cash Flow Yield for the last 52 weeks is -10.88%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqGM: ESPR

Esperion Therapeutics, Inc.

CEO	Mr. Sheldon L. Koenig
IPO Date	June 26, 2013
Location	United States
Headquarters	3891 Ranchero Drive
Employees	240
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Key trends

Past 5 years